NCT02523404

HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA）for Lung Cancer

HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA） for Lung Cancer: Clinical Trial

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 60 (actual)
• Sponsor: Fuda Cancer Hospital, Guangzhou · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the safety and efficacy of HepaSphere interventional therapy using digital subtraction angiography（DSA）for lung cancer.

Detailed description

By enrolling patients with lung cancer adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of HepaSphere interventional therapy using digital subtraction angiography（DSA）for lung cancer.

Conditions

• Lung Cancer

Interventions

Type	Name	Description
PROCEDURE	interventional therapy	lung cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）

Timeline

• Start date: 2015-05-01
• Primary completion: 2016-08-01
• Completion: 2016-08-01
• First posted: 2015-08-14
• Last updated: 2016-08-29

Locations

1 site across 1 country: China